Carlsmed, Inc. (NASDAQ:CARL) Given Average Rating of “Hold” by Brokerages

Carlsmed, Inc. (NASDAQ:CARL) has been given an average recommendation of “Hold” by the five research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $19.3333.

CARL has been the subject of a number of recent analyst reports. Truist Financial lowered their price objective on Carlsmed from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. Zacks Research upgraded Carlsmed from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 26th. The Goldman Sachs Group reduced their price objective on Carlsmed from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. BTIG Research restated a “buy” rating and set a $23.00 price objective on shares of Carlsmed in a research note on Wednesday, May 6th. Finally, Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new position in shares of Carlsmed during the third quarter worth about $33,000. JPMorgan Chase & Co. purchased a new stake in shares of Carlsmed during the third quarter worth about $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Carlsmed during the third quarter worth about $42,000. Rhumbline Advisers purchased a new stake in shares of Carlsmed during the third quarter worth about $79,000. Finally, Wells Fargo & Company MN increased its position in shares of Carlsmed by 61.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock worth $97,000 after acquiring an additional 2,989 shares during the last quarter.

Carlsmed Price Performance

Shares of NASDAQ:CARL opened at $11.07 on Friday. The company has a market cap of $300.88 million and a P/E ratio of -4.41. The company has a quick ratio of 11.67, a current ratio of 11.88 and a debt-to-equity ratio of 0.17. Carlsmed has a 52 week low of $8.50 and a 52 week high of $17.19. The business has a fifty day simple moving average of $10.36 and a 200-day simple moving average of $11.89.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. The business had revenue of $16.12 million during the quarter. Carlsmed had a negative return on equity of 60.74% and a negative net margin of 57.76%. Equities research analysts forecast that Carlsmed will post -1.35 EPS for the current year.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).